COMMUNIQUÉS West-GlobeNewswire

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21/03/2024
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su [...]
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track to deliver multiple read-outs in 2024, including updated results [...]
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21/03/2024
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage [...]
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
21/03/2024
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder TNX-2900 (intranasal [...]
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21/03/2024
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years [...]
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21/03/2024
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 [...]
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21/03/2024
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway [...]
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21/03/2024
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/ [...]
Theratechnologies entreprend l’augmentation de la dose dans l’essai clinique de phase I sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
21/03/2024
Le comité d’examen médical a approuvé la mise en place du recrutement de la prochaine cohorte de patientes, conformément au protocole d’optimisation des doses Une première patiente du groupe qui en comptera six a déjà [...]
BrightSpring Health Services Recognizes its Valuable and Esteemed Female Leaders and Staff in Celebration of Women’s History Month
21/03/2024
LOUISVILLE, Ky., March 21, 2024 (GLOBE NEWSWIRE) -- This Women’s History Month, BrightSpring Health Services, Inc. (“BrightSpring” or the “BrightSpring Health Services”) (NASDAQ: BTSG) recognizes and celebrates the [...]
XOMA Declares Quarterly Preferred Stock Dividends
21/03/2024
EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s [...]
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
21/03/2024
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended [...]
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
21/03/2024
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid- [...]
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
21/03/2024
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND- [...]
MiNK Reports Fourth Quarter and Year-End 2023 Results
21/03/2024
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies [...]
Redecan Cannabis Launches New Spring Lineup
21/03/2024
Introducing Space Age Cake Flower and Hemp’d Pre-rolls, Plus the First-of-Its-Kind 'Taster Series' Coming Soon in a Variety 10-Pack of Its Signature Redees Hemp'd Pre-Rolls TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- [...]
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in [...]
Castellum, Inc. Announces 2023 Financial Results
21/03/2024
BETHESDA, Md., March 21, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces its [...]
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
21/03/2024
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter [...]

Pages